Myogen (MYOG) Release: Four Ambrisentan Studies To Be Presented At Chest 2006 Salt Lake City
10/10/2006 11:08:55 AM
DENVER--(BUSINESS WIRE)--Myogen, Inc. (Nasdaq: MYOG), a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, today announced that four abstracts describing the effects of ambrisentan in patients with pulmonary arterial hypertension (PAH) and healthy volunteers have been selected for presentation at CHEST 2006, the scientific assembly of the American College of Chest Physicians (ACCP), to be held Oct. 21-26, 2006, at the Salt Palace Convention Center in Salt Lake City, Utah. Myogen expects to submit the ambrisentan New Drug Application to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2006.
comments powered by